JP2023512833A - 新型コロナウイルス感染症に対するｍＲＮＡワクチンの組成物及び方法 - Google Patents

新型コロナウイルス感染症に対するｍＲＮＡワクチンの組成物及び方法 Download PDF

Info

Publication number
JP2023512833A
JP2023512833A JP2022548143A JP2022548143A JP2023512833A JP 2023512833 A JP2023512833 A JP 2023512833A JP 2022548143 A JP2022548143 A JP 2022548143A JP 2022548143 A JP2022548143 A JP 2022548143A JP 2023512833 A JP2023512833 A JP 2023512833A
Authority
JP
Japan
Prior art keywords
mrna
composition
orf
seq
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512833A5 (https=
Inventor
タン、ションカオ
シェン、トン
ルー、チュン
ホー、ツーヤン
ホー、チアシー
ルー、パトリック、ワイ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RNAimmune Inc
Original Assignee
RNAimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RNAimmune Inc filed Critical RNAimmune Inc
Publication of JP2023512833A publication Critical patent/JP2023512833A/ja
Publication of JP2023512833A5 publication Critical patent/JP2023512833A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2022548143A 2020-02-07 2021-02-08 新型コロナウイルス感染症に対するｍＲＮＡワクチンの組成物及び方法 Pending JP2023512833A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062971834P 2020-02-07 2020-02-07
US62/971,834 2020-02-07
US202063058463P 2020-07-29 2020-07-29
US63/058,463 2020-07-29
US202063130581P 2020-12-24 2020-12-24
US63/130,581 2020-12-24
PCT/US2021/017149 WO2021159118A2 (en) 2020-02-07 2021-02-08 Composition and method of mrna vaccines against novel coronavirus infection

Publications (2)

Publication Number Publication Date
JP2023512833A true JP2023512833A (ja) 2023-03-29
JP2023512833A5 JP2023512833A5 (https=) 2024-02-19

Family

ID=77200778

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548143A Pending JP2023512833A (ja) 2020-02-07 2021-02-08 新型コロナウイルス感染症に対するｍＲＮＡワクチンの組成物及び方法

Country Status (11)

Country Link
US (2) US12029786B2 (https=)
EP (1) EP4100066A4 (https=)
JP (1) JP2023512833A (https=)
KR (1) KR20220143684A (https=)
CN (1) CN115297892A (https=)
AU (1) AU2021216443A1 (https=)
BR (1) BR112022015626A2 (https=)
CA (1) CA3167257A1 (https=)
IL (1) IL295360A (https=)
MX (1) MX2022009688A (https=)
WO (1) WO2021159118A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12029786B2 (en) 2020-02-07 2024-07-09 RNAimmune, Inc. Composition and method of mRNA vaccines against novel coronavirus infection
WO2021160887A1 (en) * 2020-02-14 2021-08-19 Immunor As Corona virus vaccine
JPWO2021181994A1 (https=) * 2020-03-10 2021-09-16
US20230313323A1 (en) * 2020-03-26 2023-10-05 Ionian Technologies, Llc Assays for detecting coronavirus disease 2019 (covid-19)
IL297419B2 (en) 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
EP4334479A4 (en) * 2021-05-06 2025-02-19 Lu, Shi-Long DETECTION OF VIRAL VARIANTS
JP2024530672A (ja) 2021-08-11 2024-08-23 アールエヌエーイミューン、インコーポレイテッド 新規なコロナウイルス感染症に対するｍＲＮＡワクチンの組成物および方法
WO2023020939A1 (en) * 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
CN118475371A (zh) * 2021-09-22 2024-08-09 圣诺制药公司 基于组氨酸-赖氨酸共聚物形成的改善的纳米颗粒制剂
WO2023049814A2 (en) * 2021-09-22 2023-03-30 Sirnaomics, Inc. Nanoparticle pharmaceutical compositions with reduced nanoparticle size and improved polydispersity index
CN113881806A (zh) * 2021-09-23 2022-01-04 华南理工大学 基于CRISPR/Cas12a技术检测新冠病毒和69/70突变株的方法及试剂盒
EP4183409A1 (en) * 2021-11-17 2023-05-24 Charité - Universitätsmedizin Berlin Vaccine with improved immunogenicity against mutant coronaviruses
WO2023091766A2 (en) * 2021-11-19 2023-05-25 RNAimmune, Inc. Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines
AU2022398292A1 (en) * 2021-11-29 2024-06-13 BioNTech SE Coronavirus vaccine
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
CN118556131A (zh) 2022-01-27 2024-08-27 爱思开生物科技有限公司 用于蛋白质表达的mRNA及其模板
US20250228929A1 (en) * 2022-04-03 2025-07-17 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant
US20240207389A1 (en) * 2022-04-27 2024-06-27 Northwestern University Methods for improving covid vaccine immunogenicity
DE102023002588A1 (de) * 2022-06-26 2024-01-25 BioNTech SE Coronavirus-Impfstoff
WO2024002985A1 (en) * 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
US12280104B2 (en) 2022-11-01 2025-04-22 RNAimmune, Inc. Composition and methods for MRNA vaccines against novel omicron coronavirus infections
KR102832944B1 (ko) * 2024-12-27 2025-07-15 대한민국 제2형 중증급성호흡기증후군 코로나바이러스 변이들의 공통 서열을 포함하는 코로나바이러스감염증-19 범용 백신 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004536598A (ja) * 2001-06-21 2004-12-09 エヌ．ヴイ．アントワープ イノベーティーセントラム 電気穿孔による真核細胞への線形ポリヌクレオチドの改良された形質移入
JP2009509516A (ja) * 2005-09-28 2009-03-12 ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ 転写産物の安定性と転写効率の向上をもたらすｒｎａの修飾
JP2015513897A (ja) * 2012-03-27 2015-05-18 キュアバック ゲーエムベーハーＣｕｒｅｖａｃ Ｇｍｂｈ 人工核酸分子
US20190240317A1 (en) * 2015-10-22 2019-08-08 Modernatx, Inc. Hpiv3 rna vaccines
WO2019226940A1 (en) * 2018-05-24 2019-11-28 Sirnaomics, Inc. Composition and methods of controllable co-coupling polypeptide nanoparticle delivery system for nucleic acid therapeutics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018115527A2 (en) 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
CN110520155A (zh) * 2017-02-28 2019-11-29 广州纳泰生物医药技术有限公司 预防和治疗寨卡病毒感染的rna药物制剂
PH12022551788A1 (en) * 2020-01-28 2024-02-26 Codagenix Inc DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOF
JP2023512519A (ja) 2020-01-31 2023-03-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン
US12029786B2 (en) 2020-02-07 2024-07-09 RNAimmune, Inc. Composition and method of mRNA vaccines against novel coronavirus infection
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
US20210316002A1 (en) 2020-04-14 2021-10-14 Ut-Battelle, Llc Compositions and methods for drug delivery and treating viral infections
BR112022024662A2 (pt) 2020-06-03 2023-04-04 Regeneron Pharma Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2
EP4204015A4 (en) 2020-08-31 2025-01-01 The Board of Trustees of the Leland Stanford Junior University Systems and methods for producing rna constructs with increased translation and stability
US20250213679A1 (en) 2020-10-02 2025-07-03 Celsion Corporation Polynucleotide vaccines and methods of using the same
CN115160413B (zh) 2021-04-06 2023-11-14 清华大学 一种新型冠状病毒疫苗

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004536598A (ja) * 2001-06-21 2004-12-09 エヌ．ヴイ．アントワープ イノベーティーセントラム 電気穿孔による真核細胞への線形ポリヌクレオチドの改良された形質移入
JP2009509516A (ja) * 2005-09-28 2009-03-12 ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ 転写産物の安定性と転写効率の向上をもたらすｒｎａの修飾
JP2015513897A (ja) * 2012-03-27 2015-05-18 キュアバック ゲーエムベーハーＣｕｒｅｖａｃ Ｇｍｂｈ 人工核酸分子
US20190240317A1 (en) * 2015-10-22 2019-08-08 Modernatx, Inc. Hpiv3 rna vaccines
WO2019226940A1 (en) * 2018-05-24 2019-11-28 Sirnaomics, Inc. Composition and methods of controllable co-coupling polypeptide nanoparticle delivery system for nucleic acid therapeutics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LANCET, vol. 395, JPN6025003673, January 2020 (2020-01-01), pages 565 - 574, ISSN: 0005671816 *
ZHANG, YZ. ET AL.: "Definition: Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1, complete genome", DATABASE DDBJ/EMBL/GENBANK [ONLINE], JPN6025003672, 14 January 2020 (2020-01-14), ISSN: 0005671815 *

Also Published As

Publication number Publication date
WO2021159118A3 (en) 2021-10-28
IL295360A (en) 2022-10-01
EP4100066A4 (en) 2024-05-01
KR20220143684A (ko) 2022-10-25
CA3167257A1 (en) 2021-08-12
US12029786B2 (en) 2024-07-09
WO2021159118A2 (en) 2021-08-12
MX2022009688A (es) 2022-12-15
CN115297892A (zh) 2022-11-04
US20230108926A1 (en) 2023-04-06
US20220040292A1 (en) 2022-02-10
EP4100066A2 (en) 2022-12-14
BR112022015626A2 (pt) 2022-10-11
AU2021216443A1 (en) 2022-09-08
WO2021159118A8 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
US12029786B2 (en) Composition and method of mRNA vaccines against novel coronavirus infection
CN115768521B (zh) 预防和治疗新冠病毒感染引起的严重急性呼吸道感染疾病的RNAi药物组合物及方法
JP2024503698A (ja) 変異型株ベースのコロナウイルスワクチン
US11058779B2 (en) Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection
JP2024514182A (ja) 呼吸器ウイルス組み合わせワクチン
US12280105B2 (en) Compositions and methods of mRNA vaccines against novel coronavirus infection
US20240294580A1 (en) Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines
US12280104B2 (en) Composition and methods for MRNA vaccines against novel omicron coronavirus infections
CN114832100A (zh) 一种以RBD靶向递送shRNA的nCOVsiRNA药物制备方法
KR102948559B1 (ko) 변형된 코로나바이러스 스파이크 항원 단백질 및 이의 용도
US20260083836A1 (en) Modified coronavirus spike antigen protein and uses thereof
WO2023083315A1 (zh) 一种以RBD靶向递送shRNA的nCOVsiRNA药物及合成方法和应用
WO2025024336A1 (en) Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines
CN116254256A (zh) 一种化学药物nCoVshRNA·2RBD的合成方法
CN116042656A (zh) 一种猴痘病毒mRNA疫苗及其制备方法与用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240208

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250417

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250826